Key facts
- Commodore Capital LP filed SCHEDULE 13G/A for BRIGHT MINDS BIOSCIENCES INC. Common Shares, without par value (DRUG).
- Disclosed ownership: 0.3%.
- Date of event: 31 Dec 2025.
Commodore Capital LP - 31 Dec 2025 SCHEDULE 13G/A Report for BRIGHT MINDS BIOSCIENCES INC. Common Shares, without par value (DRUG)
- Filing Manager
- Commodore Capital LP
- Reporting Manager
- Commodore Capital LP
- Symbol
- DRUG
- Disclosed Ownership
- 18,851 shares
- Ownership
- 0.3%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 16:22:37 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 14 Feb 2025
- SEC
- View on sec.gov
Key filing fact
Commodore Capital LP disclosed 0.3% ownership in BRIGHT MINDS BIOSCIENCES INC. Common Shares, without par value (DRUG) on 31 Dec 2025.
Change
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 17 Feb 2026, 16:22.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (2)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 0.3% | 18,851 | 0 | 18,851 | Michael Kramarz | Managing Partner | |
| Commodore Capital Master LP | 0.3% | 18,851 | 0 | 18,851 | Michael Kramarz | Authorized Signatory |
CIK / CUSIP context first